For patients at low-to-intermediate risk, transfemoral TAVR is a safe alternative to surgery, with comparable survival at 1 year, according to a large registry study.
For the OBSERVANT trial, Marco Barbanti, MD, of Ferrarotto Hospital (Catania, Italy), and colleagues looked at 7,618 Italian patients with aortic stenosis and low-to-intermediate surgical risk who underwent either surgery (n = 5,707) or TAVR (n = 1,911) between 2010 and 2012.
Patients were propensity-matched into 650 pairs, although surgically-treated patients still had slightly higher levels of albumin and hemoglobin and the TAVR group

A minimally invasive implant procedure is highly effective in reducing pain and disability for patients with sacroiliac joint (SIJ) dysfunction, reports a clinical trial.

The randomized controlled trial shows superior outcomes in patients undergoing minimally invasive sacroiliac joint (SIJ) fusion using triangular titanium implants, compared to nonsurgical management, according to the new research overseen by Dr. Daniel J. Cher of SI-BONE, Inc., in San Jose, Calif.

The study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics. The SIJ connects the central (sacrum) and lateral (ilium) bones of the pelvis. SIJ disruption or osteoarthritis is a common pain condition, estimated to cause 15 to 23 percent of cases of chronic low back pain.

Trial subjects had severe SIJ pain, with an average pain score of 82 on a 0-to-100-point scale. Average pain duration was longer than six years, and about two-thirds of subjects were taking opioid (narcotic) medications. Many had previously received many non-surgical SIJ treatments, and many had a history of prior spinal surgery.

Two-thirds of subjects were randomly assigned to undergo minimally invasive SIJ fusion. In this procedure, triangular titanium implants were placed through a small incision to stabilize and fuse the SIJ. Procedures were unilateral in most cases, but some subjects underwent bilateral treatment. The remaining subjects received nonsurgical treatments, such as physical therapy, steroid injections and/or radiofrequency ablation of sacral nerve root lateral branches.

Pain and other outcomes were compared at baseline and at 1, 3, 6 and 12 months. At 6 months, subjects in the nonsurgical group had the option to ‘cross over’ to the implant procedure.

Based on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment. Average pain score decreased to 30 in the surgical group versus 72 in the nonsurgical group. Seventy-three percent of subjects undergoing the implant procedure had ‘clinically significant’ reduction in disability scores, compared to just 14 percent in the nonsurgical group.

After one year, subjects assigned to SIJ fusion still had significant reductions in pain and disability, as well as improved quality of life. Thirty-five subjects from the nonsurgical group opted to undergo the implant procedure, with similarly good results. There were only a few complications related to the SIJ implant procedure. EurekAlert

An early snapshot of study outcomes suggests that the use of a processed amniotic fluid allograft may be safe and effective for the treatment of knee osteoarthritis (OA) as an alternative to hyaluronic acid (HA). Longer-lasting

Vygon, the specialist single-use medical devices group, has acquired Perouse Medical, a French company which designs, manufactures and markets cardiovascular medical devices (stents, vascular grafts and patches, radial compression and inflation systems, hemostasic valves, angiographic syringes as well as consumables for contrast media injectors for CT scanners and MRI, etc.) and long-term vascular access devices (implantable ports, PICCs, Huber needles, catheter maintenance dressings, etc.). Established in 1984, Perouse Medical generated a turnover of  

Building on wireless technology that has the potential to interfere with pain, scientists have developed flexible, implantable devices that can activate